Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Rigel Pharms
Fostamatinib is an oral tyrosine kinase inhibitor of spleen tyrosine kinase (SYK). Its active metabolite R406 inhibits signaling through Fc-activating receptors and the B-cell receptor, reducing antibody-mediated destruction of platelets. It is studied in immune thrombocytopenia, warm antibody autoimmune hemolytic anemia, IgA nephropathy, ovarian cancer, and viral pneumonia including COVID-19.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04629703 | Phase 3 | Covid19 | Completed | RIGL |
| NCT02612558 | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia | Completed | RIGL |
| NCT02112838 | Phase 2 | IGA Nephropathy | Completed | RIGL |
| NCT03246074 | Phase 1 | Ovarian Cancer | Completed | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Covid19IGA NephropathyOvarian CancerPneumoniaPneumonia, ViralSARS (Severe Acute Respiratory Syndrome)SARS PneumoniaWarm Antibody Autoimmune Hemolytic Anemia
Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →